Perrigo Co. has received final approval from the Food and Drug Administration for its abbreviated new drug application (ANDA) for morphine sulfate 100ml/5% oral solution.


Perrigo, morphine sulfate oral solution, opioid pain medication, narcotic pain medication, Schedule II controlled substance, opioid analgesic








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Perrigo launches opioid pain medication

August 9th, 2012

ALLEGAN, Mich. – Perrigo Co. has received final approval from the Food and Drug Administration for its abbreviated new drug application (ANDA) for morphine sulfate 100ml/5% oral solution.

The company said Wednesday that it will start shipping the product, a narcotic pain medication, immediately.

Morphine sulfate oral solution is a Schedule II controlled substance, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate.

Generic annual sales of the medication are approximately $26 million, according to Wolters Kluwer Health data cited by Perrigo.

Advertisement